Dehydroepiandrosterone as neurosteroid: Neuroendocrine effects in post-menopausal women

Journal of Endocrinological Investigation

Volumn 22, Issue 10 SUPPL. 1, 1999, Pages 19-23

  Genazzani, A R ^a   Stomati, M ^a   Bernardi, F ^a   Monteleone, P ^a   Morittu, A ^a   Luisi, M ^b  

^a UNIVERSITY OF PISA   (Italy)

^b CNR   (Italy)

Author keywords

Dehydroepiandrosterone; Neurosteroids

Indexed keywords

PRASTERONE; PRASTERONE SULFATE;

FEMALE; HUMAN; METABOLISM; NEUROSECRETION; PHYSIOLOGY; POSTMENOPAUSE; REVIEW;

DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HUMANS; NEUROSECRETORY SYSTEMS; POSTMENOPAUSE;

EID: 0033253892     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Majewska M.D. Neurosteroids: endogenous bimodal modulators of the GABA-A receptor. Mechanism of action and physiological significance. Progr. Neurobiol. 1992, 38: 379-395.
2. Corpechot C., Young J., Calvel M., Wehrey C., Veltz J.N., Touyer G., Mouren M., Prasad V.V.K., Banner C., Sjovall J., Baulieu E.E., Robel P. Neurosteroids: 3β-Hydroxy-Δ5-Pregnan-20-One and its precursors in the brain, plasma, and steroidogenic glands of male and female rats. Endocrinology 1993, 133:1003-1009.
3. Thijssen J.H.H., Nieuwenhuyse H. DHEA: a comprehensive review. The Partenon Publishing Group, New York, 1999.
4. Parker L.N., Odell W.D. Control of adrenal androgen secretion. Endocr. Rev. 1980, 4:392-410.
5. Mellon S.H. Neurosteroids: biochemistry, modes of action, and clinical relevance. J. Clin. Endocrinol. Metab. 1994, 78:1003-1008.
6. Majewska M.D., Demirgoren S., Spivak C.E., London E.D. The neurosteroid DHEA is an allosteric antagonist of the GABAA receptor. Brain Res 1990, 526:143-146
7. Yamaji T., Ibayashi H. Serum dehydroepiandrosterone sulphate in normal and pathological conditions. J Clin Endocrinol Metab 1969, 29: 273-278.
8. Liu C.H., Laughlin G.A., Fischer U.G., Yen S.S.C. Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in postmenopausal women: evidence for a reduced 17,20 desmo-lase enzymatic activity. J. Clin. Endocrinol. Metab. 1990, 71: 900-906.
9. Barret-Connor E., Khaw K., Yen S.S.C. A prospective study of DS mortality and cardiovascular disease. N. Engl. J. Med. 1986, 315:1519-1524.
10. Helzlsouer K.J., Gordon G.B., Alberg A., Bush T.L., Comstock G.W. Relationship of prediagnostic serum levels of DHEA and DS to the risk of developing premenopausal breast cancer. Cancer Res. 1992, 52:1-4.
11. Bulbrook R.D., Hayward J.L., Spicer C.C. Relation between urinary androgen and corticoid secretion excretion and subsequent breast cancer. Lancet 1975, 2:395-398.
12. Thoman M.L., Weigle W.O. The cellular and subcellular bases of immunosenescence. Adv. Immunol. 1989, 46: 221-261.
13. Mortola J.F., Yen S.S.C. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J. Clin. Endocrinol. Metab. 1990, 71: 696-704.
14. Berr C., Lafont S., Debuire B., Dartigues J.-F., Baulieu E.E. Relationship of dehydroepiandrosterone sulphate in the elderly functional, and mental status, and short-term mortality: a French community-based study. Proc. Natl. Acad. Sci. USA 1996, 93:13410-13415.
15. Morales A.J., Nolan J.J., Nelson J.C., Yen S.S.C. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab. 1994, 78:1360-1367.
16. Wolf O.T., Neumann O., Hellhammer D.H., Geiben A.C., Strasburger C.J., Dressendorfer R.A., Pirke K.M., Kirschbaum C. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J. Clin. Endocrinol. Metab. 1997, 82: 2363-2367.
17. Wolkowitz O.M., Reus V.I., Roberts E., Manfredi F., Chan T., Raum W.J., Ormiston S., Johnson R., Canick J., Brizendine L., Weingartner H. Dehydroepiandrosterone (DHEA) treatment of depression.Biol. Psychiatry 1997, 41: 311-318.
18. Genazzani A.R., Petraglia F., Cleva M., Brilli G., Mercuri N., De Ramundo B.M., Volpe A. Norgestimate increases pituitary and hypothalamic concentrations of immunoreactive beta-en-dorphin. Contraception 1989, 40: 605-613.
19. Genazzani A.R., Petraglia F., Mercuri N., Brilli G., Genazzani A.D., Bergamaschi M., De Ramundo B.M., Volpe A.Effect of steroid hormones and antihormones on hypothalamic beta-endorphin concentrations in intact and castrated female rats.J. Endocrinol. Invest. 1990, 13: 91-96.
20. Petraglia F., Comitini G., Genazzani A.R., β-Endorphin in human reproduction. In: Herz A. (Ed.), Opioids II. Springer-Verlag, Berlin, 1993, pp. 763-780.
21. Stomati M., Bersi C., Rubino S., Palumbo M., Comitini G., Genazzani A.D., Petraglia F., Genazzani A.R. Neuroendocrine effects of different oestradiol-progestin regimens in postmenopausal women. Maturitas, 1997, 28:127-135.
22. Schneider H.P.G., Genazzani A.R. A new approach in the treatment of climateric disorders. De Gruiter W., New York, 1992, pp. 134-154.